natgillin/translations-raw huggingface dataset:
IONSYS will then shut down and will not deliver any further doses.
IONSYS se bo nato izklopil in ne bo dovedel nadaljnjih odmerkov.
80 doses
80 odmerkih
You can take a dose whenever you need it for your pain, or just before you do an activity that may increase your pain (such as physical therapy, getting out of bed, etc.).
Odmerek lahko vzamete, kadar ga potrebujete zaradi bolečin, ali tik pred dejavnostmi, ki bi lahko povečale bolečine (npr. fizioterapijo, vstajanjem iz postelje).
Abuse or intentional misuse of IONSYS may result in overdose and/or death.
Zloraba ali namerna napačna uporaba zdravila IONSYS lahko povzroči preveliko odmerjanje in/ali smrt.
Remove the sachet and the controller.
Odstranite vrečko in upravljalnik.
In this situation, special patient care and observation are appropriate.
V teh okoliščinah sta potrebna posebna oskrba in opazovanje bolnika.
Remember that only the patient may touch the dosing button.
Ne pozabite, da se sme samo bolnik dotakniti gumba za odmerjanje.
Contact with the hydrogel should be avoided.
Treba je preprečiti stik s hidrogelom.
All adverse reactions are listed by System Organ Class and frequency: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); and rare (≥1/10,000
Vsi neželeni učinki so navedeni po organskih sistemih in pogostnosti: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100) in redki (≥ 1/10.000 do < 1/1.000).
The design of the system allows separate disposal of the hydrogel housing and the Controller.
Zasnova sistema omogoča ločeno odlaganje hidrogelnega ohišja in upravljalnika.
You control your own treatment under the guidance of your doctor or nurse in hospital.
Zdravljenje nadzorujete sami pod vodstvom zdravnika ali medicinske sestre v bolnišnici.
Your doctor will discuss the possible risks and potential benefits of using IONSYS while you are pregnant.
Zdravnik se bo z vami pogovoril o morebitnih tveganjih in koristih uporabe zdravila IONSYS med nosečnostjo.
An alternative application site should be chosen.
Izbrati je treba drugo mesto aplikacije.
Tell your doctor or nurse if:
Zdravniku ali medicinski sestri morate povedati, če:
IONSYS is not recommended for children and adolescents under 18 years of age due to the lack of data in these patients.
Zdravilo IONSYS se ne priporoča otrokom in mladostnikom, mlajšim od 18 let, zaradi pomanjkanja podatkov pri teh bolnikih.
Patients with a prior history of drug dependence/alcohol abuse are more at risk to develop dependence and abuse in opioid treatment.
Bolniki z anamnezo odvisnosti od drog ali zlorabe alkohola so v večji nevarnosti za razvoj odvisnosti in zlorabo pri zdravljenju z opioidi.
Reversal of the narcotic effect may also result in acute onset of pain and release of catecholamines.
Odprava narkotičnega učinka lahko pripelje tudi do akutnega pojava bolečine in sproščanja kateholaminov.
Thus, the adverse reaction profile does not suggest a meaningful difference in safety compared to patients younger than 65 years of age.
Profil neželenih učinkov torej ne kaže pomembnih razlik v varnosti v primerjavi z bolniki, mlajšimi od 65 let.
years.
2 leti
As illustrated in Table 1 below, IONSYS (fentanyl hydrochloride) was superior to placebo in all studies.
Kot je prikazano v preglednici 1 spodaj, je bilo zdravilo IONSYS (fentanilov hidroklorid) boljše od placeba v vseh študijah.
• Choose healthy, unbroken skin (non-irritated and nonirradiated skin) site on the chest or upper outer arm ONLY.
• Izberite zdravo, nepoškodovano kožo (nerazdraženo in neobsevano) SAMO na prsih ali zunanjem delu nadlahti.
Fentanyl pharmacokinetics are similar with both single and multiple 24 hour applications.
Farmakokinetika fentanila je podobna pri posamezni in večkratni 24-urni aplikaciji.
This side of the system contains material called “gels” which you should not normally come into contact with.
Ta stran sistema vsebuje dva gela, ki se ju navadno ne smete dotikati.
For management of respiratory depression, immediate countermeasures include removing the IONSYS system and physically or verbally stimulating the patient.
Med takojšnjimi protiukrepi za obvladovanje depresije dihanja so odstranitev sistema IONSYS in telesna ali verbalna stimulacija bolnika.
The plasma protein binding of fentanyl is 80% to 85%.
Vezava fentanila na plazemske beljakovine je od 80- do 85-odstotna.
Therefore, the use of any of these medicinal products concomitantly with IONSYS requires special patient care and observation.
Zato sta pri uporabi katerega koli od teh zdravil sočasno s sistemom IONSYS potrebna posebna oskrba in opazovanje bolnika.
Physicians should evaluate patients for a history of drug abuse and follow such patients closely.
Zdravnik mora oceniti bolnikovo zgodovino zlorabe zdravil in drog ter takšne bolnike pozorno spremljati.
Long-lasting or any non-opioid analgesics were not permitted.
Uporaba dolgodelujočega ali katerega koli neopioidnega analgetika ni bila dovoljena.
Patients should be advised not to drive or operate machinery if they experience somnolence, dizziness, or visual disturbance.
Bolnikom je treba svetovati, naj ne vozijo ali upravljajo strojev, če so zaspani, omotični ali imajo motnje vida.
• Do not let your family or friends start IONSYS for you.
• Ne dovolite, da družinski člani ali prijatelji aktivirajo vaš sistem IONSYS.
• severe headache (migraine)
• hud glavobol (migrena)
Pharmacotherapeutic group: Analgesics; phenylpiperidine derivatives; ATC code: N02AB03.
Farmakoterapevtska skupina: analgetiki; derivati fenilpiperidina; oznaka ATC: N02AB03.
• IONSYS is ready to be used again and you may start another dose at any time you need it.
• Sistem IONSYS je takrat pripravljen za ponovno uporabo in sprožite lahko nov odmerek, kadar koli ga boste potrebovali.
The half-life of the antagonist may be short; therefore, repeated administration or infusion of the antagonist may be necessary.
Razpolovni čas antagonista je lahko kratek, zato bosta morda potrebna večkratno dajanje ali infuzija antagonista.
• low calcium/glucose/potassium in blood serum
• nizka raven kalcija/glukoze/kalija v krvnem serumu
A carcinogenicity study (daily subcutaneous injections of fentanyl hydrochloride for two years in Sprague Dawley rats) did not induce any findings indicative of oncogenic potential.
V študiji kancerogenosti (dnevne podkožne injekcije fentanilovega hidroklorida v obdobju dveh let pri podganah Sprague Dawley) ni bilo ugotovitev, ki bi kazale na onkogeni potencial.
Administration during childbirth is not recommended because fentanyl crosses the placenta and the fetal respiratory centre is sensitive to opiates.
Uporaba med porodom se ne priporoča, ker fentanil prehaja skozi posteljico in je dihalni center ploda občutljiv za opiate.
The safety of IONSYS has not been established in patients with American Society of Anesthesiologists (ASA) physical status classification IV (i.e. patients with a severe systemic disease that is a constant threat to life).
Varnost zdravila IONSYS ni dokazana pri bolnikih z zdravstvenim stanjem IV na lestvici ASA (American Society of Anesthesiologists), tj. bolnikih s hudo sistemsko boleznijo, ki pomeni stalno smrtno nevarnost.
• you have a very slow heart rate, low blood pressure, or other serious heart problem
• če imate zelo počasen srčni utrip, nizek krvni tlak ali drugo resno težavo s srcem;
Fentanyl can be abused in a manner similar to other opioid agonists.
Fentanil se lahko zlorabi podobno kot drugi opioidni agonisti.
If you are an older patient your doctor will monitor you more carefully as IONSYS may affect you more than a younger patient.
Če ste starejši, vas bo zdravnik natančneje spremljal, saj ima lahko zdravilo IONSYS pri vas večji učinek kot pri mlajših bolnikih.
• Information highlighting that IONSYS is a patient-controlled device to be used in a hospital setting only and that standard practices for monitoring patients using such devices should be followed by healthcare professionals.
• Informacije, ki poudarjajo, da je Ionsys pripomoček, ki ga nadzoruje bolnik in se uporablja samo v bolnišnicah ter da morajo zdravstveni delavci upoštevati standardne prakse spremljanja bolnikov, ki uporabljajo take pripomočke.
With intravenous administration, the initial distribution half-life is approximately 6 minutes; the second distribution half-life is 1 hour, and the terminal half-life is 13 hours.
Pri intravenski uporabi je začetni razpolovni čas porazdelitve približno 6 minut, drugi razpolovni čas je 1 ura in končni 13 ur.
The European Medicines Agency has deferred the obligation to submit the results of studies with IONSYS in one or more subsets of the paediatric population for the treatment of acute pain.
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom IONSYS za eno ali več podskupin pediatrične populacije, zdravljenih zaradi akutne bolečine.
Its secondary pharmacological effects are respiratory depression, bradycardia, hypothermia, constipation, miosis, physical dependence and euphoria (see section 5.2).
Sekundarni farmakološki učinki so depresija dihanja, bradikardija, hipotermija, zaprtost, mioza, telesna odvisnost in evforija (glejte poglavje 5.2).
Patients were enrolled shortly after major surgery if they were not opioid tolerant, were expected to have an uncomplicated recovery, and required at least 24 hours of parenteral opioid treatment.
Bolniki so začeli sodelovati v študiji kmalu po večji operaciji, če niso imeli tolerance na opioide, če je bilo pričakovano nezapleteno okrevanje in če so potrebovali vsaj 24-urno parenteralno zdravljenje z opioidi.
Before any surgery, the healthcare professional should ensure that the patient has been properly informed on how to use IONSYS post-operatively.
Pred vsakim kirurškim posegom mora zdravstveni delavec poskrbeti, da je bolnik ustrezno obveščen o tem, kako mora uporabljati sistem IONSYS po operaciji.
None of the four demographic factors studied [weight (lean/obese), age, race, or gender] had a significant effect on active substance exposure (AUC) following use of IONSYS.
Noben od štirih preučevanih demografskih dejavnikov [telesna masa (majhna/čezmerna), starost, rasa ali spol] ni imel pomembnega vpliva na izpostavljenost zdravilu (AUC) po uporabi sistema IONSYS.
Each time you are given a new IONSYS you may find you initially need to have more doses to relieve your pain than later on during treatment.
Vsakič, ko dobite nov sistem IONSYS, boste morda ugotovili, da na začetku potrebujete za lajšanje bolečin več odmerkov kot pozneje med zdravljenjem.
Opioids may obscure the clinical course of patients with head injury.
Opioidi lahko prikrijejo klinični potek pri bolnikih s poškodbami glave.
- Do not take it off or attempt to put it back on yourself.
- Sami sistema ne odstranite in ne poskusite ga znova namestiti.
The main binding protein is alpha-1-acid glycoprotein, but both albumin and lipoproteins contribute to some extent.
Glavna vezna beljakovina je alfa-1-kisli glikoprotein, do neke mere pa tudi albumin in lipoproteini.
In general, the maximum serum fentanyl concentration occurs approximately 15 minutes after the initiation of a dose.
V splošnem je serumska koncentracija fentanila najvišja približno 15 minut po začetku dovajanja odmerka.
Patients could remain in their respective study up to 72 hours if they required parenteral opioid analgesia for this duration.
Bolniki so lahko ostali v študiji do 72 ur, če so toliko časa potrebovali parenteralno opioidno analgezijo.
Respiratory depression following an overdose may outlast the duration of action of the opioid antagonist.
Depresija dihanja po prevelikem odmerjanju lahko traja dlje od delovanja opioidnega antagonista.
Concomitant use of analgesics was not allowed after 3 hours in Studies C-2000-007 and CAPSS-320.
Po 3 urah v študijah C-2000-007 in CAPSS-320
Each new system should be placed on a new skin site.
Vsak nov sistem je treba namestiti na nov kožni predel.
IONSYS only delivers the medicine when you activate it, so you control how much medicine you receive.
Sistem IONSYS dovaja zdravilo samo, kadar ga sprožite, tako da lahko nadzorujete, koliko zdravila prejmete.
Error message/feedback
Sporočilo o napaki/povratna informacija
2 years Use immediately after opening.
Uporabite takoj po odprtju.
In Study CAPSS-319, half the patients in each group received rofecoxib perioperatively and in Study FEN-PPA-401 patients were allowed non-opioid analgesics throughout the study period.
V študiji CAPSS-319 je pol bolnikov v vsaki skupini perioperativno prejelo rofekoksib in v študiji FEN-PPA-401 so bili v celotnem obdobju študije dovoljeni neopioidni analgetiki.
• tightness/tension in muscles, muscle pain
• zategovanje/napetost v mišicah, bolečine v mišicah
• you are taking muscle relaxants (prescribed for back pain), or if you are undergoing general
• jemljete mišične relaksante (predpisane za bolečine v hrbtu) ali če boste potrebovali splošno anestezijo;
In such patients, opioids may decrease respiratory drive and increase airway resistance.
Pri takšnih bolnikih lahko opioidi zmanjšajo frekvenco dihanja in povečajo upor v dihalnih poteh.
Fentanyl should not be used in patients who may be particularly susceptible to the intracranial effects of CO2 retention, such as those with evidence of increased intracranial pressure, impaired consciousness, or coma.
Fentanil se ne sme uporabljati pri bolnikih, ki so lahko še posebno občutljivi za intrakranialne učinke zadrževanja CO2, npr. tistih z znaki zvišanega intrakranialnega tlaka, motnjami zavesti ali pri bolnikih v komi.
• Do not touch the sticky side of IONSYS.
• Ne dotikajte se lepilnega dela sistema IONSYS.
• Align the matching shapes of the controller and the drug unit and firmly press the two parts together at both ends.
• Poravnajte ujemajoča se dela upravljalnika in zdravilne enote ter trdno pritisnite oba dela skupaj na obeh koncih.
Hypoventilation, hypotension, and profound sedation or coma may occur.
Nastopijo lahko hipoventilacija, hipotenzija in globoka sedacija ali koma.
Only you know how much pain you are having, and only you should operate IONSYS to start a dose of medicine.
Samo vi veste, kako močne bolečine imate, in samo vi smete sprožiti sistem IONSYS za odmerjanje zdravila.
The efficacy and safety of IONSYS for treatment of acute, moderate to severe postoperative pain was evaluated in seven controlled studies in 1763 IONSYS patients: three placebo-controlled studies and four active-controlled studies.
Učinkovitost in varnost zdravila IONSYS pri zdravljenju akutnih, zmernih do hudih pooperativnih bolečin so ocenili v sedmih nadzorovanih študijah pri 1763 bolnikih: treh s placebom nadzorovanih študijah in štirih z zdravilno učinkovino nadzorovanih študijah.
• Remove and discard the clear plastic liner covering the adhesive.
• Odstranite in zavrzite prozorno plastično folijo, ki prekriva lepilo.
The digital display will show the number of doses that have been
Digitalni prikazovalnik bo prikazal število dovedenih odmerkov.
- Do not let the IONSYS system get wet because it could stop working or fall off.
- Sistem IONSYS se ne sme zmočiti, ker bi lahko prenehal delovati ali odpadel.
Additional analyses suggest that the surgical procedure type did not influence the trends in efficacy endpoints and the efficacy of IONSYS was similar across the range of body mass indices studied (< 25 to > 40 kg/m2
Dodatne analize so pokazale, da vrsta kirurškega postopka ni vplivala na trende opazovanih dogodkov učinkovitosti, in učinkovitost sistema IONSYS je bila podobna v celotnem preiskovanem razponu indeksov telesne mase (od < 25 do ≥ 40 kg/m2 ITM).
If you do use more IONSYS than you should then you may experience shortness of breath, difficulty breathing, rapid and shallow breathing, or feeling faint.
Če uporabite več zdravila IONSYS, kot bi smeli, se lahko pojavijo zasoplost, težave z dihanjem, hitro in plitvo dihanje ali občutek omedlevice.
• you have a severe or persistent lung disease, or any breathing problems
• če imate hudo ali dolgotrajno pljučno bolezen ali kakršne koli težave z dihanjem;
Another published article of 52 elderly Japanese post-operative patients receiving continuous intravenous (IV) fentanyl infusion (0.5-1.5 µg/kg/h) showed increased fentanyl exposure in the CYP3A5*3 group (3*/3*) than in the 1* carrier group.
Drug objavljen članek o 52 starejših japonskih bolnikih, ki so po operaciji prejemali neprekinjeno intravensko (IV) infuzijo fentanila (0,5-1,5 µg/kg/h), razkriva povečano izpostavljenost fentanilu v skupini CYP3A5*3 (3*/3*) v primerjavi s skupino 1*.
As shown below, the primary endpoint, proportion of patients reporting “Good or Excellent” ratings for the two methods of pain relief in all four studies demonstrated equivalence, with each 95% confidence interval contained within the prespecified ± 10% equivalence boundaries.
Kot je prikazano v nadaljevanju, je primarni opazovani dogodek, delež bolnikov, ki je ocenil obe metodi lajšanja bolečine kot »dobri ali odlični« v vseh štirih študijah, izkazal enakovrednost, pri čemer je bil vsak 95-odstotni interval zaupanja vsebovan v vnaprej opredeljenih ±10-odstotnih mejah enakovrednosti.
Hepatic disease may delay elimination.
Bolezni jeter lahko zapoznijo izločanje.
If system beeps again, then remove and dispose of system, and place a new system on a different skin site.
Če sistem znova začne piskati, ga odstranite in zavrzite ter namestite nov sistem na drug kožni predel.
• anaemia (low blood count)
• anemija (majhno število krvnih celic)
The primary endpoint in each placebo-controlled study was the proportion of withdrawals due to inadequate analgesia during the period from 3 to 24-hours after IONSYS application.
Primarni opazovani dogodek v vsaki s placebom nadzorovani študiji je bil delež umikov zaradi neustrezne analgezije v obdobju od 3 do 24 ur po namestitvi sistema IONSYS.
IONSYS is composed of an electronic controller and a drug unit with two hydrogels.
Sistem IONSYS je sestavljen iz elektronskega upravljalnika in zdravilne enote z dvema hidrogeloma.
Each IONSYS carton contains 6 systems.
Vsaka škatla vsebuje 6 sistemov IONSYS.
• you have severe headaches, have had a significant head injury, or have a brain tumour
• če imate hude glavobole, ste imeli hujšo poškodbo glave ali imate možganski tumor;
There are no clinical data on the effects of fentanyl on fertility.
Ni kliničnih podatkov o vplivih fentanila na plodnost.
Dose proportionality has been demonstrated from 25 to 60 micrograms per dose.
Linearnost/nelinearnost Sorazmernost odmerka je bila dokazana za od 25 do 60 mikrogramov na odmerek.
Consequently, the patient may activate IONSYS more frequently to maintain fentanyl blood levels.
Bolnik bo morda zaradi tega aktiviral sistem IONSYS pogosteje, da ohrani raven fentanila v krvi.
The concomitant use of partial opioid agonists/antagonists (e.g. buprenorphine, nalbuphine, pentazocine) is not recommended.
Sočasna uporaba delnih opioidnih agonistov/antagonistov (npr. buprenorfina, nalbufina, pentazocina) se ne priporoča.
The assembled IONSYS product measures 47 mm x 75 mm.
Sestavljen izdelek IONSYS meri 47 mm x 75 mm.
• Checklist for monitoring inadequate product disposal to ensure healthcare professionals understand the dangers of inappropriate handling and accidental exposure to the IONSYS
• Kontrolni seznam za spremljanje neustreznega odstranjevanja sistema zaradi zagotavljanja, da zdravstveni delavci razumejo nevarnosti nenamerne izpostavljenosti sistemu Ionsys in nepravilnega ravnanja z njim.
Due to the well-known potential of abuse of fentanyl, physicians should evaluate patients for a history of drug abuse (see section 4.4).
Zaradi znane možnosti zlorabe fentanila mora zdravnik oceniti bolnikovo zgodovino zlorabe zdravil in drog (glejte poglavje 4.4).
In patients with chronic obstructive pulmonary disease or patients with conditions pre-disposing them to hypoventilation, more severe adverse reactions may be experienced.
Pri bolnikih s kronično obstruktivno pljučno boleznijo ali bolnikih z boleznimi, zaradi katerih so dovzetni za hipoventilacijo, se lahko pojavijo hujši neželeni učinki.
The concomitant use of ritonavir or other potent or moderate CYP3A4 inhibitors and IONSYS is not recommended unless the patient is closely monitored.
Sočasna uporaba ritonavirja ali drugih močnih ali zmernih zaviralcev CYP3A4 z zdravilom IONSYS se ne priporoča, razen ob pozornem spremljanju bolnika.
Supplemental intravenous opioid medication (fentanyl or morphine) was only allowed during the first 3 hours of IONSYS or PCA morphine treatment.
Dodatno intravensko opioidno zdravilo (fentanil ali morfin) je bilo dovoljeno samo v prvih 3 urah zdravljenja z zdravilom IONSYS ali zdravljenja PCA z morfinom.
If severe or persistent hypotension occurs, hypovolaemia should be considered and the condition should be managed with appropriate parenteral fluid therapy or other interventions as needed, based upon the clinical judgment of the treating health care professional.
Če se pojavi huda ali persistentna hipotenzija, je treba upoštevati možnost hipovolemije in stanje obvladovati z ustreznim parenteralnim nadomeščanjem tekočine ali drugimi ukrepi, ki so morda potrebni na podlagi klinične presoje lečečega zdravnika.
• The doctor or nurse will put IONSYS on your skin, and take it off or replace it when needed.
• Zdravnik ali medicinska sestra bosta namestila sistem IONSYS na vašo kožo in ga odstranila ali zamenjala, ko bo potrebno.
Patients with genetic polymorphisms affecting CYP3A4 and CYP3A5
Bolniki z genetskimi polimorfizmi, ki vplivajo na CYP3A4 in CYP3A5
• Dispose of remainder of the system, containing electronics, according to hospital procedures for battery waste.
• Preostanek sistema, ki vsebuje elektronske dele, zavrzite po bolnišničnih postopkih za baterijske odpadke.
Each tray is packaged in a folding cardboard carton.
Vsak podstavek je pakiran v kartonsko škatlo.
Significant respiratory depression may occur with IONSYS; patients must be observed for these effects (see section 4.9).
Pri uporabi sistema IONSYS se lahko pojavi pomembna depresija dihanja; bolnike je treba opazovati zaradi teh učinkov (glejte poglavje 4.9).
Pharmacokinetic /pharmacodynamic relationship
Farmakokinetično/farmakodinamično razmerje
See package leaflet for disposal information.
Glejte navodilo za uporabo za informacije o odstranjevanju.
Detailed information on this medicine is available on the European Medicines Agency (EMA) web site: http://www.ema.europa.eu/.
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila: http://www.ema.europa.eu/.
The most commonly reported adverse reactions were nausea, vomiting, and application site reactions such as erythema and pruritus.
Najpogosteje opisani neželeni učinki so navzea, bruhanje in reakcije na mestu aplikacije, kot sta eritem in pruritus.
In this study 28 paediatric patients, 6 to 16 years old, were treated with IONSYS fentanyl 40 micrograms after experiencing inadequate analgesia with IONSYS fentanyl 25 micrograms.
V tej študiji so 28 pediatričnih bolnikov, starih od 6 do 16 let, zdravili s sistemom IONSYS s 40 mikrogrami fentanila, potem ko je bila analgezija s sistemom IONSYS s 25 mikrogrami fentanila neustrezna.
Around 75% of fentanyl is excreted into the urine, mostly as metabolites, with less than 10% as unchanged active substance.
Okoli 75 % fentanila se izloči z urinom, večinoma v obliki presnovkov, z manj kot 10-odstotno vsebnostjo nespremenjene zdravilne učinkovine.
Your doctor or nurse will remove the IONSYS system before you leave hospital.
Zdravnik ali medicinska sestra bosta sistem odstranila, preden boste zapustili bolnišnico.
Prior to launch of IONSYS in each Member State the Marketing Authorisation Holder (MAH) must agree about the content and format of the educational programme, including communication media, distribution modalities, and any other aspects of the programme, with the National Competent Authority.
Imetnik dovoljenja za promet z zdravilom se mora pred začetkom trženja zdravila Ionsys dogovoriti s pristojnim nacionalnim organom v vsaki državi članici o vsebini in obliki izobraževalnega programa, vključno s sredstvi obveščanja, načini distribucije in vseh drugih vidikih programa.
• Blinking red light for 15 seconds
• 15 sekund utripa rdeča lučka